Overcoming Ovarian Cancer Chemoresistance presents non-overlapping review chapters that discuss the state of the field in overcoming chemoresistance of ovarian cancer and treatment options before and following recurrence, considering the genetic makeup of the ovarian cancer patient and her tumor. With the uptake of both germline and somatic gene testing, clinicians can obtain a more comprehensive understanding of ovarian tumors and this book provides information to link the genetic makeup of a tumor (or patient) with the best available treatment. The book discusses topics such as strategies to fight chemo-resistance in ovarian cancer, circulating DNA as a monitor of response, BRCA mutations, ovarian cancer stem cells, immunotherapy and vaccines. Additionally, it brings a list of promising agents at clinical and pre-clinical stage that will impact the treatment in the near future. This book is a valuable source for cancer researchers, oncologists and several members of biomedical field who need to understand how to battle chemoresistance in ovarian cancer. Provides a comprehensive view of both biological and genetic determinants of resistance, as well as technical approaches to monitor response Discusses genetic reversions as a unique alteration and a new field of study Includes a chapter on upcoming and promising agents that are in the pre-clinical and early clinical space, to set the stage for future directions in the field

Overcoming Drug Resistance in Gynecologic Cancers provides up-to-date information related to important gynecologic cancers and focuses on mechanisms of drug resistance, genetics, signaling, immunology, health disparities, nanotechnology, economic considerations and financial impacts. The book covers not only drug resistance but also important means to reverse resistance both in the laboratory and clinic. The book discusses topics such as lifestyle, nutrition and risk of gynecologic cancers, the financial impact of drug resistance, chemosensitizing agents and targeted therapies in cervical, endometrial and ovarian cancer, immunotherapy to overcome drug resistance, and genetic polymorphisms in gynecologic cancers. Additionally, it discusses ethnic and racial health disparity perspectives and future developments in chemosensitizing activities to reverse drug resistance in gynecologic cancers. It is a valuable resource for cancer researchers, oncologists, clinicians and other biomedical field members who are interested in new approaches to improve chemotherapy outcome in patients with gynecologic cancers. Provides a comprehensive resource with all the details needed for readers to understand and follow information Encompasses schematics, diagrams and flow charts in all chapters to help readers easily follow critical information Presents tables and figures especially developed to summarize the information with appropriate statistical rigor and to show details of clinical specimens such as pathological, radiological characteristics, and/or laboratory biomarkers

Offers women with ovarian cancer support and resources to help them deal with the physical and emotional impact of their disease.

In an era of promising advances in cancer research, there are considerable and even alarming gaps in the fundamental knowledge and understanding of ovarian cancer. Researchers now know that ovarian cancer is not a single disease-several distinct subtypes exist with different origins, risk factors, genetic mutations, biological behaviors, and prognoses. However, persistent questions have impeded progress toward improving the prevention, early detection, treatment, and management of ovarian cancers. Failure to significantly improve morbidity and mortality during the past several decades is likely due to several factors, including the lack of research being performed by specific disease subtype, lack of definitive knowledge of the cell of origin and disease progression, and incomplete understanding of genetic and non-genetic risk factors. Ovarian Cancers examines the state of the science in ovarian cancer research, identifies key gaps in the evidence base and the challenges to addressing those gaps, considers opportunities for advancing ovarian cancer research, and examines avenues for translation and dissemination of new findings and communication of new information to patients and others. This study makes recommendations for public- and private-sector efforts that could facilitate progress in reducing the incidence of morbidity and mortality from ovarian cancers.

"Ovarian Cancer: A Comprehensive Resource for Patients and Families" is a vital guide for anyone impacted by ovarian cancer. This book provides a thorough exploration of the disease, offering clarity and support through each stage, from initial diagnosis to treatment and beyond.Understanding Ovarian CancerThe journey begins with an introduction to ovarian cancer, including its epidemiology, types, and stages. Gain an understanding of the ovaries' role in the female reproductive system and how cancer affects these vital organs.Recognizing Risk Factors and Early DetectionLearn about the genetic and environmental risk factors associated with ovarian cancer and the importance of early detection. This book covers the challenges of early detection, screening methods, and the critical role of diagnostic testing.Navigating Diagnosis and TreatmentDelve into the diagnostic process, including understanding pathology reports and the role of biopsy. Explore comprehensive treatment options, from surgery to chemotherapy, radiotherapy, and the latest in targeted therapy and immunotherapy.Managing Side Effects and ComplicationsUnderstand and manage the side effects and complications associated with treatment, including pain management and coping with emotional and physical stress.Nutrition and Lifestyle during TreatmentDiscover the importance of nutrition and lifestyle changes during treatment, with practical advice on diet, exercise, and lifestyle modifications for optimal health.Psychological Impact and SupportFind guidance on coping with the emotional and psychological impacts of ovarian cancer. Learn about the importance of psychological support, counseling, and the role of community and support groups.Recurrence and Long-term ManagementAddress the challenges of recurrence and long-term management of ovarian cancer, including strategies for monitoring, follow-up care, and understanding recurrence.Advances in ResearchStay informed about the latest advances in ovarian cancer research, emerging treatments, and the future direction of care and clinical trials.Special Considerations in CareGain insights into special considerations for ovarian cancer care, including issues relevant to young women, fertility, and menopausal management post-treatment.Advocacy and AwarenessUnderstand the importance of raising awareness and advocacy for ovarian cancer. Discover support networks and resources available to empower patients and families."Ovarian Cancer: A Comprehensive Resource for Patients and Families" is an indispensable tool, offering comfort, clarity, and hope to those navigating the complexities of ovarian cancer. It is a comprehensive guide that not only provides medical information but also addresses the emotional and practical aspects of coping with the disease.

Ovarian cancer management is a rapidly changing field with new treatment agents available as a result of a greater understanding of the pathogenesis of this disease. In addition, both surgical and chemotherapeutic treatment strategies are evolving to maximise response in this disease. This book brings together leading specialists from around the world to discuss and outline a variety of new concepts in ovarian cancer, ranging from molecular biology and genetics through screening to both surgical and chemotherapeutic management.

This new volume presents the latest research on therapies for ovarian cancer. Ovarian cancer is cancer that begins in the cells that constitute the ovaries, including surface epithelial cells, germ cells, and the sex cord-stromal cells. Cancer cells that metastasize from other organ sites to the ovary (most commonly breast or colon cancers) are not then considered ovarian cancer. According to the American Cancer Society, ovarian cancer accounts for 4 percent of all cancers among women and ranks fifth as a cause of their deaths from cancer. The American Cancer Society statistics for ovarian cancer estimate that there will be 25,400 new cases and 14,300 deaths in 2003. The death rate for this disease has not changed much in the last 50 years. Unfortunately, almost 70 percent of women with the common epithelial ovarian cancer are not diagnosed until the disease is advanced in stage -- i.e., has spread to the upper abdomen (stage III) or beyond (stage IV). The 5-year survival rate for these women is only 15 to 20 percent, whereas the 5-year survival rate for stage I disease patients approaches 90 percent and for stage II disease patients approaches 70 percent. Ovarian tumors are named according to the type of cells the tumor started from and whether the tumor is benign or cancerous. The three main types of ovarian tumors are: Epithelial Tumors, Germ Cell Tumors and Stromal Tumors.